We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSHP
RNS Number : 6951L
JPMorgan Securities Plc
20 April 2018
AMMENT
INCREASED EQUITY PURCHASES BY 34,552 TO 710,062
INCREASED EQUITY SALES BY 2,541 TO 562,730
ADDED EQUITY SWAP SALES OF 37,093
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION (a) Name of exempt principal trader: J.P. Morgan Securities Plc ---------------------------------------------------------- ---------------------------------------------------------- (b) Name of offeror/offeree in relation to whose relevant Shire plc securities this form relates: Use a separate form for each offeror/offeree ---------------------------------------------------------- ---------------------------------------------------------- (c) Name of the party to the offer with which exempt Joint Financial Adviser to Takeda Pharmaceutical Company principal trader is connected: Limited ---------------------------------------------------------- ---------------------------------------------------------- (d) Date dealing undertaken: 16 April 2018 ---------------------------------------------------------- ---------------------------------------------------------- (e) In addition to the company in 1(b) above, is the Yes, Takeda Pharmaceutical Company Limited exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A" ---------------------------------------------------------- ---------------------------------------------------------- 2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
Hot Features
Premium
(a) Purchases and sales
Class of relevant Purchases/ sales Total number of Highest price per unit Lowest price per unit
security securities paid/received paid/received
(GBP) (GBP)
----------------------- ----------------- ------------------------ ----------------------- -----------------------
Ordinary Shares Purchases 710,062 36.7750 35.3300
Sales 562,730 36.7800 35.3900
----------------------- ----------------- ------------------------ ----------------------- -----------------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities (GBP)
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
Ordinary Shares Equity Swaps Long 87 35.5889
84,174 35.5900
284 35.6984
34,552 36.1144
247 36.3939
541 36.4041
6,455 36.4245
207 36.4251
1,230 36.4275
2,195 36.4344
28,875 36.4381
63 36.4402
3,053 36.4849
57 36.4971
1,028 36.5182
3,973 36.5192
6,511 36.6353
4,782 36.7410
Short 94 35.5900
39,118 35.5916
2,042 35.5928
132 35.6112
23,308 35.6114
2,531 35.6313
762 35.6835
21,363 35.6981
510 35.7215
33,095 35.7539
32,810 35.7856
18,746 35.7936
5,632 35.8667
1,077 35.9171
8,630 35.9339
447 35.9477
20,601 35.9558
1,154 35.9631
6,147 36.0206
6,260 36.1220
3,377 36.1514
9,636 36.2192
6,942 36.2447
17,276 36.3250
951 36.3313
694 36.3421
8,428 36.3867
2,541 36.4270
34,552 36.4516
2,131 36.4821
545 36.6725
------------------------- -------------------- ------------------------- ------------------------- ---------------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option (GBP) European unit
relates etc. (GBP)
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
(GBP)
----------------------- -------------------- ----------------------- --------------------- -----------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable) (GBP)
e.g. subscription, conversion
--------------------------- ------------------------------- -------- -------------------------------------
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
----------------------------------------------------------------------------------------------
None
----------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt
principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
-----------------------------------------------------------------------------------------------
None
-----------------------------------------------------------------------------------------------
Date of disclosure: 20 April 2018
--------------------- --------------
Contact name: Alwyn Basch
--------------------- --------------
Telephone number: 020 7742 7407
--------------------- --------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FERLLFFDSSIIFIT
(END) Dow Jones Newswires
April 20, 2018 13:25 ET (17:25 GMT)
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
